MedTrace Logo

Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine

NCT03160820 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 873

Last updated 2017-05-19

No results posted yet for this study

Summary

This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose immunization with MMR vaccine or as a first dose to 18 month-old subjects with one dose immunization with measles-rubella(MR).

Conditions

  • Measles
  • Mumps
  • Rubella
  • Adverse Event Following Immunisation

Interventions

BIOLOGICAL

Measles, mumps and rubella Combined Vaccine, Live

Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.

Sponsors & Collaborators

  • Beijing Tiantan Biological Products Co., Ltd.

    collaborator INDUSTRY

  • Centers for Disease Control and Prevention, China

    lead OTHER_GOV

Principal Investigators

  • Jiang Wu · Beijing Center for Diseases Control and Prevention

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-12-31
Completion
2017-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160820 on ClinicalTrials.gov